Howard Gurney
Macquarie University
H-index: 58
Oceania-Australia
Top articles of Howard Gurney
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study. | Martin H Voss Howard Gurney Vagif Atduev Cristina Suárez Miguel Ángel Climent | 2024/2/1 | |
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index … | Jeanny B Aragon-Ching Daniel P Petrylak Srikala S Sridhar Shilpa Gupta Petros Grivas | 2024/2/1 | |
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine | Toni K Choueiri Piotr Tomczak Se Hoon Park Balaji Venugopal Tom Ferguson | 2024/4/18 |
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non‐clear‐cell renal cell carcinoma | BJU international | Ciara Conduit Ian D Davis Jeffrey C Goh Ganessan Kichenadasse Howard Gurney | 2024/2 |
Preliminary data from a dose-escalation phase 1 study with HP518, an AR PROTAC degrader: Safety, tolerability, pharmacokinetics (PK), and first assessment of anti-tumor … | Arun Azad Howard Gurney Craig Underhill Lisa Horvath Mark Voskoboynik | 2024/2/1 | |
Clinical validation of circulating GDF15/MIC‐1 as a marker of response to docetaxel and survival in men with metastatic castration‐resistant prostate cancer | The Prostate | Kate L Mahon Sarah IM Sutherland Hui Ming Lin Martin R Stockler Howard Gurney | 2024/3/27 |
Urological Oncology: Adrenal, Renal, Ureteral, and Retroperitoneal Tumors | Journal of Urology | M Pilar Laguna | 2024/1/15 |
Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort | Clinical Pharmacology & Therapeutics | Anna M Mc Laughlin Thomas Helland Fenja Klima Stijn LW Koolen Ron HN van Schaik | 2024/3/18 |
Nivolumab plus cabozantinib (N+ C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial. | Maria Teresa Bourlon Bernard Escudier Mauricio Burotto Thomas Powles Andrea B Apolo | 2024/2/1 | |
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study | Journal of Clinical Oncology | Robert J Motzer Camillo Porta Masatoshi Eto Thomas Powles Viktor Grünwald | 2024/1 |
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy | Journal of Clinical Oncology | Jonathan Strosberg Edward Wolin Beth Chasen Matthew Kulke David Bushnell | 2018/9/9 |
Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC). | Toni K Choueiri Piotr Tomczak Se Hoon Park Balaji Venugopal Thomas Ferguson | 2024/2/1 | |
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial | ESMO open | T Powles M Burotto B Escudier AB Apolo MT Bourlon | 2024/5/1 |
Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E. | Marinela Augustin Brigitte Laguerre Capucine Baldini Ahmed H Zedan Enrique Gonzalez-Billalabeitia | 2024/2/1 | |
UNICAB: Cabozantinib in locally advanced or metastatic non‐clear cell renal cell carcinoma post immunotherapy or in those unsuitable for immunotherapy (ANZUP 1802). | David William Pook Carole A Harris Emma Link Jeffrey C Goh Francis Parnis | 2024/2/1 | |
Psychosocial Factors Associated with Cognitive Function in Prostate Cancer Survivors on Hormonal Treatments: A Systematic Review | Journal of Alzheimer's Disease | Mayra L Estrella Ramon A Durazo-Arvizu Linda C Gallo Wassim Tarraf Carmen R Isasi | 2021/1/1 |
Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia | Howard Gurney Timothy D Clay Niara Oliveira Shirley Wong Ben Tran | 2023/12 | |
Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate … | Thomas Powles Robert J Motzer Laurence Albiges Cristina Suárez Fabio AB Schutz | 2023/2/20 | |
Electronic cigarettes and health outcomes: umbrella and systematic review of the global evidence | Emily Banks Amelia Yazidjoglou Sinan Brown Mai Nguyen Melonie Martin | 2023/4/3 | |
Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+ P) vs sunitinib (S) in patients (pts) with advanced renal cell … | Robert J Motzer Camillo Porta Masatoshi Eto Thomas Powles Viktor Grünwald | 2023/6/1 |
